文献速递肺结节与肺癌

SABRTooth:SABR对比手术治疗高危外周I期NSCLC的随机对照可行性研究

SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.
PubMed 文献 · Eur Respir J · 2020-11-12

SABRTooth是在英国开展的多中心随机对照可行性研究,纳入因手术并发症风险较高而被认为适合SABR或手术的外周I期非小细胞肺癌患者,计划1:1随机分配至SABR或手术。研究主要终点为月平均招募率,实际随机24例(SABR 14例,手术10例),月平均招募率为1.7例,低于目标3例。结论认为在英国国家医疗服务体系内开展SABR对比手术的III期随机对照试验不可行,患者既有的治疗偏好是招募障碍,且随机至手术组的患者中有相当比例拒绝手术而选择SABR。

要点

  • SABRTooth研究显示在英国NHS内随机分配高危I期NSCLC患者至SABR或手术不可行
  • 月平均招募率仅1.7例,低于目标3例
  • 患者既有的治疗偏好是招募的主要障碍

核心结论

  • 在英国国家医疗服务体系内,将手术并发症风险较高的外周I期NSCLC患者随机分配至SABR或手术的III期随机对照试验不可行。
  • 患者既有的治疗偏好是招募的主要障碍,且相当比例随机至手术组的患者拒绝手术而选择SABR。
  • SABR仍是手术的替代选择,需要新的研究方法来明确哪些患者从非手术途径获益。

研究设计与样本

  • SABRTooth为英国多中心随机对照可行性研究。
  • 目标人群为因手术并发症风险较高而被认为适合SABR或手术的外周I期NSCLC患者。
  • 计划随机54例患者,1:1分配至SABR或手术,主要终点为月平均招募率。

主要发现

  • 2015年7月至2017年1月期间,共318例患者被考虑纳入研究,其中205例(64.5%)被判定不符合纳入标准。
  • 在被评估为符合纳入标准的106例(33.3%)患者中,24例(22.6%)被随机分配至SABR(n=14)或手术(n=10)。
  • 不参与的关键主题为治疗偏好,43例(41%)偏好非手术治疗,19例(18%)偏好手术。
  • 月平均招募率为1.7例患者,低于目标3例。
  • 15例患者接受了分配的治疗:SABR组12例,手术组3例。

临床怎么用

  • 在临床实践中,应认识到高危外周I期NSCLC患者对SABR或手术存在既有的治疗偏好,可能影响随机对照试验的招募和治疗分配。
  • SABR仍可作为手术的替代选择,但需进一步研究明确哪些患者从非手术途径获益。

局限性

  • 本研究为可行性研究,样本量小(随机24例),主要终点为招募率而非疗效比较。
  • 研究在英国国家医疗服务体系内进行,结论外推至其他医疗体系需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Stereotactic ablative radiotherapy (SABR) is a well-established treatment for medically inoperable peripheral stage I nonsmall cell lung cancer (NSCLC). Previous nonrandomised evidence supports SABR as an alternative to surgery, but high-quality randomised controlled trial (RCT) evidence is lacking. The SABRTooth study aimed to establish whether a UK phase III RCT was feasible. DESIGN AND METHODS: SABRTooth was a UK multicentre randomised controlled feasibility study targeting patients with peripheral stage I NSCLC considered to be at higher risk of surgical complications. 54 patients were planned to be randomised 1:1 to SABR or surgery. The primary outcome was monthly average recruitment rates. RESULTS: Between July 2015 and January 2017, 318 patients were considered for the study and 205 (64.5%) were deemed ineligible. Out of 106 (33.3%) assessed as eligible, 24 (22.6%) patients were randomised to SABR (n=14) or surgery (n=10). A key theme for nonparticipation was treatment preference, with 43 (41%) preferring nonsurgical treatment and 19 (18%) preferring surgery. The average monthly recruitment rate was 1.7 patients against a target of three. 15 patients underwent their allocated treatment: SABR n=12, surgery n=3. CONCLUSIONS: We conclude that a phase III RCT randomising higher risk patients between SABR and surgery is not feasible in the National Health Service. Patients have pre-existing treatment preferences, which was a barrier to recruitment. A significant proportion of patients randomised to the surgical group declined and chose SABR. SABR remains an alternative to surgery and novel study approaches are needed to define which patients benefit from a nonsurgical approach.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Franks KN, McParland L, Webster J, et al. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. Eur Respir J. 2020. PMID: 32616595. doi:10.1183/13993003.00118-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。